	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S177-PMC2581757	PMC2581757	11/2008	S177-PMC2581757	['no effect of Vitamins C and E, however, was observed on Gpx levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 28, 'E'), ('PR_000008210', 'glutathione peroxidase 1', 56, 'GPx')]
S178-PMC2581757	PMC2581757	11/2008	S178-PMC2581757	['Grx activity declined significantly (27%) in preeclamptics who had not consumed Vitamins C and E (group a), but its activity did not fall significantly (5.5%) in patients who had used these Vitamins regularly as mentioned above.']	N/A	N/A	[('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 0, 'GRx'), ('CHEBI_27300', 'vitamin D', 80, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 95, 'E'), ('CHEBI_33277', 'gamma-tocotrienol', 190, 'vitamins')]
S72-PMC3296991	PMC3296991	2/2012	S72-PMC3296991	['caption (table-wrap): table 2\n\ncharacteristics of african american and non–african american participants.african american ( n = 40)non–african american ( n = 40) p –valuemean (sd)1rangemean (sd)1rangegestational age at Birth (weeks)39.7 (1.6)37.1–42.039.4 (1.1)37.1–41.3nsbirth weight (g)3429 (512)2372–45323419 (526)2290–4460nsage at dxa scan (days)12.8 (3.4)8–2113.4 (3.5)9–21nsmaternal parity2.1 (1.2)1–51.8 (0.8)1–3nsmaternal age (years)25.4 (5.2)18–3928.3 (5.6)18–380.02maternal bmi (kg/m2)132.2 (29.6, 35.0)18.8–49.930.9 (28.3, 33.7)20.5–66.0nsmaternal total Vitamin D intake (iu/days)698 (246)0–1326684 (253)184–1316nsmaternal 25(Oh)D (nmol/l)69.1 (26.1)33.5–118.582.3 (30.3)20.8–151.70.04cord 25(Oh)D1,2(nmol/l)36.0 (31.7, 40.8)16.7–87.548.2 (41.4, 56.1)14.1–157.50.004maternal pth (pg/ml)129.4 (24.9, 34.8)9.5–66.129.3 (23.6, 36.4)6.2–102.0Nscord pth (pg/ml)1,26.1 (4.6, 8.0)2.0–50.73.7 (2.8, 4.7)2.0–82.50.009cord Balp (u/l)1123.9 (112.2, 137.1)71.4–272.5107.7 (98.4, 117.9)58.3–197.80.04wbbmc (g)61.3 (13.1)38.3–95.961.9 (12.1)35.4–83.3nswbbmc (g per (kg^1.31))10.9 (0.9)9.1–12.711.4 (1.0)8.9–14.90.06 n % n % p –valuesexns\xa0\xa0\xa0male22551845\xa0\xa0\xa0female18452255racen/a\xa0\xa0\xa0african american401000–\xa0\xa0\xa0hispanic0–1230\xa0\xa0\xa0asian0–820\xa0\xa0\xa0caucasian0–410\xa0\xa0\xa0mixed/other0–1640maternal Vitamin D supplementationns\xa0\xa0\xa0<400 iu/day717.51127.5\xa0\xa0\xa0≥400 iu/day3382.52972.5feedingns\xa0\xa0\xa0exclusively Breast Fed1127.51947.5\xa0\xa0\xa0exclusively formula Fed1332.5615.0\xa0\xa0\xa0mixed1640.001537.5\n1geometric means and 95% confidence intervals are presented for variables requiring log transformation to conform to normal distribution;2undetectable samples assigned as 2/3 detection limit.']	N/A	N/A	[('GO_0007567', 'parturition', 219, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('CHEBI_17792', 'organohalogen compound', 637, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 640, 'D'), ('CHEBI_73281', '(2S)-versicolorone(1-)', 701, '25(OH)D1'), ('UBERON_0002328', 'notochord', 848, '0NSCord'), ('SO_0000153', 'BAC', 924, 'BALP'), ('CHEBI_27300', 'vitamin D', 1275, 'vitamin D'), ('UBERON_0000310', 'breast', 1377, 'breast'), ('GO_0032304', 'negative regulation of icosanoid secretion', 1384, 'fed1127'), ('GO_0044347', 'cell wall polysaccharide catabolic process', 1422, 'fed1332')]
S78-PMC3347007	PMC3347007	4/2012	S78-PMC3347007	['44.4% had sufficient total Vitamin D intake.nutrients-04-00259-t001_table 1\n\ncaption (table-wrap): table 1\n\nintake of Vitamin D Supplements in the danish national Birth cohort during Gestational weeks 21–25 ( n = 68,447) *.daily Vitamin D dosen (%)0 µg22,214 (32.5)women who took Vitamin D supplements46,233 (67.5)>0 µg and ≤2.5 µg1020 (1.5)>2.5 µg and <5 µg2110 (3.1)≥5 µg and <7.5 µg16,710 (24.4)≥7.5 µg and <10 µg1114 (1.6)≥10 µg25,279 (36.9)\n* based on information from the Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 118, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 126, 'D'), ('CHEBI_33341', 'titanium atom', 128, 'supplements'), ('GO_0007567', 'parturition', 163, 'Birth'), ('GO_0007565', 'female pregnancy', 183, 'gestational'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_33290', 'food', 478, 'food')]
S83-PMC3365381	PMC3365381	3/2011	S83-PMC3365381	['other Molecules (Benzpyrene, Vitamins A and D) also can imprint the Brain, is manifested in the change of biogenic amine levels of the Brain and csf (tekes et al.2007a,b,2009a,b,c).']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 6, 'molecules'), ('CHEBI_29865', 'benzo[a]pyrene', 17, 'benzpyrene'), ('CHEBI_27300', 'vitamin D', 29, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 44, 'D'), ('UBERON_0000955', 'brain', 68, 'brain'), ('UBERON_0000955', 'brain', 135, 'brain')]
S54-PMC3406997	PMC3406997	5/2012	S54-PMC3406997	['caption (table-wrap): table 1\n\ncomposition of diet administered to Pigs during the study\xa0sows14–27\u2009day of Life28–42\u2009day of Life7–12\u2009week of Life13–19\u2009week of Lifefrom 20\u2009week of Life ingredient \xa0\xa0\xa0\xa0\xa0\xa0wheat middlings (%)35.047.045.040.030.025.0barley middlings (%)35.020.036.035.530.030.0soybean meal (%)15.018.010.017.515.010.0rye middlings (%)10.5–––22.032.5sauen-profi1* (%)3.5–––––ferkel-profi2* (%)–4.04.04.0––Josamin3* (%)––––3.02.5megajoule* (%)–5.02.02.5––cytromin duo* (%)0.51.01.00.5––trilac* (%)–5.02.0–––Limestone (%)0.3–––––Soybean oil (%)0.7––––– composition \xa0\xa0\xa0\xa0\xa0\xa0dry matter (%)88.4589.3288.8188.6488.3087.25crude protein (%)16.3519.3115.5317.7716.8015.18me (mj/kg)12.9613.2112.8912.9412.9913.07crude fibre (%)3.563.413.433.683.503.34crude fat (%)2.353.062.292.371.661.68ash (%)5.436.105.505.704.764.22starch (%)45.8240.8546.6643.9846.7249.42ca (%)0.810.840.800.810.750.63p (%)0.600.580.530.560.470.44available p (%)0.160.150.150.150.140.13na (%)0.170.220.210.210.170.15mg (%)0.170.190.190.190.190.17Carbohydrates (%)3.904.984.854.403.543.50lys (%)0.911.311.041.200.990.83met (%)0.280.440.380.400.310.28met\u2009+\u2009cys (%)0.590.780.690.740.630.57trp (%)0.200.270.210.230.200.18thr (%)0.580.840.680.780.630.55vitamin A (ie)18,00065,00038,00030,00012,00010,000vitamin D3(ie)1,5007,8004,3203,6501,9801,650vitamin E (mg)90307202145180150vitamin c (mg)30.038.035.033.0––Vitamin K (mg)2.12.52.52.51.401.20vitamin b1(mg)2.12.52.52.51.401.20Vitamin B2(mg)4.46.56.56.54.243.52vitamin B6(mg)4.25.05.05.04.23.5vitamin B12(μg)14.038.035.035.035.030.0\n1the Vitamin-Mineral concentrate contained per 1\u2009kg of diet: l-lysine 6.0\u2009%, methionine 1.0\u2009%, threonine 0.5\u2009%, Ca 20.0\u2009%, P 7.5\u2009%, Na 5.0\u2009%, Mg 2.5\u2009%, Vitamin a 600,000\u2009iu, Vitamin D350,000\u2009iu, Vitamin E 3,000\u2009mg, Vitanin C 1,000\u2009mg, Vitamin K3100\u2009mg, Vitamin b190\u2009mg, Vitamin B2200\u2009mg, Vitamin b6180, vitamin b121,330\u2009μg, niacin 1,200, Pantothenic Acid 660\u2009mg, Folic Acid 50\u2009mg, Choline Chloride 15,000\u2009mg, Biotin 4,000\u2009μg, Cu 875\u2009mg, zn 5,250\u2009mg, Mn 3,000\u2009mg, fe 4,000\u2009mg, j 75\u2009mg, co 10\u2009mg, Se 10\u2009mg.\n2the Vitamin-Mineral Concentrate contained per 1\u2009kg of diet: l-lysine 10.0\u2009%, methionine 3.3\u2009%, threonine 4.2\u2009%, Tryptophan 0.2\u2009%, ca 15.0\u2009%, p 4.0\u2009%, Na 4.5\u2009%, Vitamin A 500,000\u2009iu, Vitamin D350,000\u2009iu, Vitamin E 3,300\u2009mg, Vitanin C 4,000\u2009mg, Vitamin K3125\u2009mg, Vitamin B170\u2009mg, Vitamin B2150\u2009mg, vitamin b6130, vitamin b121,700\u2009μg, niacin 1,700, Pantothenic Acid 500\u2009mg, Folic Acid 40\u2009mg, Choline Chloride 17,500\u2009mg, Biotin 6,000\u2009μg, phytase 12,500 u, Cu 400\u2009mg, zn 1,000\u2009mg, Mn 500\u2009mg, Fe 800\u2009mg, j 55\u2009mg, Co 10\u2009mg, Se 10\u2009mg.\n3the Vitamin-Mineral concentrate contained per 1\u2009kg of diet: l-lysine 8.0\u2009%, methionine 2.0\u2009%, threonine 2.0\u2009%, Ca 21.0\u2009%, p 3.0\u2009%, Na 5.0\u2009%, Mg 2.0\u2009%, Vitamin A 400,000\u2009iu, Vitamin D366,000\u2009iu, Vitamin E 6,000\u2009mg, vitamin k375\u2009mg, Vitamin B170\u2009mg, Vitamin B2150\u2009mg, vitamin b6130, vitamin b121,000\u2009μg, niacin 900, Pantothenic Acid 500\u2009mg, Folic Acid 40\u2009mg, Choline Chloride 12,000\u2009mg, Biotin 2,500\u2009μg, phytase 10,000 u, Cu 160\u2009mg, zn 660\u2009mg, Mn 160\u2009mg, Fe 748\u2009mg, j 50\u2009mg, Co 11\u2009mg, Se 13\u2009mg.\n*josera erbacher gmbh & co., kleinheubach, germany.']	N/A	N/A	"[('NCBITaxon_10088', 'Mus <genus>', 67, 'pigs'), ('UBERON_0007118', 'umbilicus', 106, 'life28'), ('UBERON_0000104', 'life cycle', 123, 'life7'), ('UBERON_0007118', 'umbilicus', 140, 'life13'), ('UBERON_0006376', 'premacula segment of distal straight tubule', 158, 'lifeFrom'), ('UBERON_0000104', 'life cycle', 178, 'life'), ('PR_000009682', 'ceramide synthase 6', 414, 'Josamin3'), ('CHEBI_18131', 'licodione', 515, 'Limestone'), ('CHEBI_36945', 'sulfaniumyl group', 536, 'Soybean'), ('CHEBI_33807', 'penturonic acid', 1012, '17Carbohydrates'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1224, 'A'), ('PR_000001177', 'D(2) dopamine receptor', 1274, 'D3'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1318, 'E'), ('CHEBI_28384', 'vitamin K', 1373, 'Vitamin K'), ('PR_000011032', 'neutrophil cytosol factor 4', 1439, '20Vitamin B2'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 1483, 'B6'), ('CHEBI_27778', 'abequose', 1515, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 1515, 'B12'), ('CHEBI_33229', 'vitamin (role)', 1552, 'vitamin'), ('CHEBI_46662', 'mineral', 1560, 'mineral'), ('CHEBI_32588', 'potassium chloride', 1659, 'Ca'), ('CHEBI_53758', 'PAP', 1670, 'P'), ('CHEBI_25614', 'nylons', 1679, 'Na'), ('CHEBI_34829', 'Medrysone', 1689, 'Mg'), ('CHEBI_33229', 'vitamin (role)', 1699, 'vitamin'), ('CHEBI_52330', 'glycerophosphatidylethanolamine', 1721, 'vitamin D350'), ('CHEBI_27300', 'vitamin D', 1742, 'vitamin E'), ('CHEBI_66356', 'Verrucoside', 1762, 'vitanin C'), ('CHEBI_85626', 'N-hydroxyhexadecenoylsphingosine-1-phosphocholine', 1782, 'vitamin K3100'), ('CHEBI_33229', 'vitamin (role)', 1800, 'vitamin'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 1817, 'vitamin B2200'), ('CHEBI_33229', 'vitamin (role)', 1835, 'vitamin'), ('CHEBI_7916', 'pantothenic acid', 1885, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 1910, 'folic acid'), ('CHEBI_133341', 'choline chloride', 1928, 'choline chloride'), ('CHEBI_15956', 'biotin', 1956, 'biotin'), ('CHEBI_17996', 'chloride', 1973, 'Cu'), ('CHEBI_25614', 'nylons', 1997, 'Mn'), ('CHEBI_37972', 'phosphorus-32 atom', 2042, 'Se'), ('CHEBI_33229', 'vitamin (role)', 2057, 'vitamin'), ('CHEBI_36134', 'glutaconate(2-)', 2065, 'mineral concentrate'), ('CHEBI_86267', 'nitrotyrosine', 2165, 'Tryptophan'), ('CHEBI_25614', 'nylons', 2203, 'Na'), ('CHEBI_27300', 'vitamin D', 2213, 'vitamin A'), ('CHEBI_52330', 'glycerophosphatidylethanolamine', 2235, 'vitamin D350'), ('CHEBI_27300', 'vitamin D', 2256, 'vitamin E'), ('CHEBI_66356', 'Verrucoside', 2276, 'vitanin C'), ('CHEBI_85626', 'N-hydroxyhexadecenoylsphingosine-1-phosphocholine', 2296, 'vitamin K3125'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 2314, 'vitamin B170'), ('CHEBI_52359', ""tris(4,4'-diphenyl-2,2'-bipyridine)ruthenium(II) chloride"", 2331, 'vitamin B2150'), ('CHEBI_7916', 'pantothenic acid', 2399, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 2424, 'folic acid'), ('CHEBI_133341', 'choline chloride', 2442, 'choline chloride'), ('CHEBI_15956', 'biotin', 2470, 'biotin'), ('CHEBI_17996', 'chloride', 2505, 'Cu'), ('CHEBI_25614', 'nylons', 2529, 'Mn'), ('CHEBI_33290', 'food', 2540, 'Fe'), ('CHEBI_33290', 'food', 2560, 'Co'), ('CHEBI_37972', 'phosphorus-32 atom', 2570, 'Se'), ('CHEBI_27300', 'vitamin D', 2585, 'vitamin-'), ('CHEBI_46662', 'mineral', 2593, 'mineral'), ('CHEBI_32588', 'potassium chloride', 2692, 'Ca'), ('CHEBI_25614', 'nylons', 2712, 'Na'), ('CHEBI_34829', 'Medrysone', 2722, 'Mg'), ('CHEBI_27300', 'vitamin D', 2732, 'vitamin A'), ('CHEBI_33739', 'di-mu-sulfido-diiron(0)', 2754, 'vitamin D366'), ('CHEBI_27300', 'vitamin D', 2775, 'vitamin E'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 2812, 'vitamin B170'), ('CHEBI_52359', ""tris(4,4'-diphenyl-2,2'-bipyridine)ruthenium(II) chloride"", 2829, 'vitamin B2150'), ('CHEBI_7916', 'pantothenic acid', 2895, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 2920, 'folic acid'), ('CHEBI_133341', 'choline chloride', 2938, 'choline chloride'), ('CHEBI_15956', 'biotin', 2966, 'biotin'), ('CHEBI_17996', 'chloride', 3001, 'Cu'), ('CHEBI_25614', 'nylons', 3023, 'Mn'), ('CHEBI_33290', 'food', 3034, 'Fe'), ('CHEBI_33290', 'food', 3054, 'Co'), ('CHEBI_37972', 'phosphorus-32 atom', 3064, 'Se')]"
S119-PMC3586494	PMC3586494	2/2013	S119-PMC3586494	['contrary to Vitamins A and E, cord Vitamin C levels were higher than maternal levels, and no significant correlation between Cord and maternal Vitamin C levels was present.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 21, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 27, 'E'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin C'), ('PR_000004900', 'complement C3', 43, 'C'), ('UBERON_0002240', 'spinal cord', 125, 'cord'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin C')]
S4-PMC3616124	PMC3616124	4/2013	S4-PMC3616124	['this is a secondary analysis of a randomized controlled trial in which 10,154 low-risk women received daily Vitamin C and E, or placebo, from 9-16 weeks Gestation until Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'E'), ('GO_0007565', 'female pregnancy', 153, 'gestation'), ('GO_0007567', 'parturition', 169, 'delivery')]
S135-PMC3616124	PMC3616124	4/2013	S135-PMC3616124	['increased Preeclampsia risk in hispanic Hp 2-2 women was specific to the large quantities of Vitamins C and E in study Supplements.']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 10, 'preeclampsia'), ('PR_000008443', 'huntingtin-associated protein 1', 40, 'Hp 2'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_33341', 'titanium atom', 119, 'supplements')]
S157-PMC3641012	PMC3641012	4/2013	S157-PMC3641012	['point (nmol/l) 45.5[41.0, 49.9]44.4[39.7, 49.1]42.1[39.1, 45.1]difference in 25(Oh)D between groups at day 0 (nmol/l) –1.1[−5.3, 7.6]– decay rate (days-1or mcg-1) 0.04[0.03, 0.05]0.04[0.03, 0.05]0.0003[0.0002, 0.0004]δ25(Oh)D at steady-state in Placebo group (nmol/l) –−7.1[−12.3, -1.9]– effect of Vitamin D on δ25(Oh)D at steady-state (nmol/l) 94.4[83.9, 104.9]101.6[89.7, 113.4]398.3[88.7, 107.9]attained steady-state 25(Oh)D (nmol/l) 139.9[130.1, 149.6]138.8[127.4, 150.2]140.4[131.2, 149.6]adjusted r20.720.750.75 aic –3907.23904.4\n180 participants in the Vitamin D group, contributing 220 specimens.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 77, '25(OH ... D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 221, 'OH)D'), ('CHEBI_26130', 'biological pigment', 245, 'placebo'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 314, '(OH)D'), ('CHEBI_17792', 'organohalogen compound', 423, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 426, 'D'), ('CHEBI_27300', 'vitamin D', 560, 'vitamin D')]
S1-PMC3827489	PMC3827489	10/2013	S1-PMC3827489	['hypovitaminosis D (Vitamin D insufficiency or deficiency) is observed not only in Adults but also in infants, children, and adolescents.']	N/A	N/A	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0007023', 'adult organism', 82, 'adults')]
S567-PMC4113768	PMC4113768	7/2014	S567-PMC4113768	['results: 260 Pregnant women were randomised to placebo ( n = 87), lower dose ( n = 87) or higher dose ( n = 86) vitamin D. in comparison with placebo, Serum 25(Oh)D concentrations were higher during Pregnancy and infancy in both the lower and higher dose Vitamin D groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 160, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 163, 'D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
S15-PMC4188019	PMC4188019	1/2010	S15-PMC4188019	['in the Liver, Vitamin D is hydroxylated to 25-Hydroxyvitamin D. subsequent hydroxylation in the Kidney forms the active Metabolite, 1,25-Oh vitamin D.\nin Pregnancy, there is a 2-fold higher concentration of 1,25-Oh Vitamin D in maternal Serum due to activity of Placental 1-α-hydroxylase (novakovic et al., 2009).']	N/A	N/A	[('UBERON_0002107', 'liver', 7, 'liver'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 43, '25-hydroxyvitamin D'), ('UBERON_0002113', 'kidney', 96, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 120, 'metabolite'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 134, '25-OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 148, 'D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('CHEBI_72639', '13-HODE', 207, '1,25-OH'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('UBERON_0001977', 'blood serum', 237, 'serum'), ('UBERON_0001987', 'placenta', 262, 'placental')]
S18-PMC4251419	PMC4251419	12/2014	S18-PMC4251419	['the Synthesis Of Vitamin D following uvb irradiation Of The Skin\nuvb Photons are absorbed by 7-Dehydrocholestrol in the Epidermis and are converted into pre-Vitamin D which undergoes a thermal isomerisation to Formvitamin D. this then undergoes two Hydroxylation reactions, first in the Liver to form 25-Hydroxyvitamin D (25(Oh)D) and then in the Kidney to form the active Metabolite, 1,25-Dihydroxyvitamin D (1,25(Oh)2D).']	N/A	N/A	[('GO_0030474', 'spindle pole body duplication', 4, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0001554', 'luteolysis', 53, 'of     skin'), ('CHEBI_30212', 'photon', 69, 'photons'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 93, '7-dehydrocholestrol'), ('UBERON_0007376', 'outer epithelium', 120, 'epidermis'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_72459', 'Dig-Cy5', 210, 'formvitamin D'), ('GO_0044444', 'cytoplasmic part', 249, 'hydroxylation'), ('UBERON_0002107', 'liver', 287, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 301, '25-hydroxyvitamin D'), ('CHEBI_63056', 'zinc cation', 322, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 328, 'D'), ('UBERON_0002113', 'kidney', 347, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 373, 'metabolite'), ('CHEBI_67472', '15-epi-lupulin B', 385, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 410, '1,25(OH)2D')]
S181-PMC4302429	PMC4302429	1/2015	S181-PMC4302429	['to clarify the activity of Vitamin D against m. tuberculosis , liu and colleagues [41] observed that activation of the toll-like receptor Tlr1/2 by a lipoprotein extracted from m. tuberculosis reduced the viability of Intracellular m. tuberculosis in Human Monocytes and Macrophages, concomitant with an increased Expression of the vitamin D receptors and of Cyp27B1 (the enzyme that produces 1,25(Oh)2D) in these cells.']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('PR_000001155', 'Toll-like receptor 4', 138, 'TLR1'), ('GO_0005622', 'intracellular anatomical structure', 218, 'intracellular'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human'), ('CL_0000576', 'monocyte', 257, 'monocytes'), ('CL_0000235', 'macrophage', 271, 'macrophages'), ('GO_0010467', 'gene expression', 314, 'expression'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 340, 'D'), ('PR_000006101', 'cytochrome P450 1A1', 359, 'CYP27B1'), ('CHEBI_37983', 'sulfur-35 atom', 393, '1'), ('CHEBI_17996', 'chloride', 394, ','), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 395, '25(OH)2D')]"
S90-PMC4405493	PMC4405493	4/2015	S90-PMC4405493	['ten percent of our study population was Vitamin D deficient with a Serum concentration less than 20 ng/ml (50 nmol/l); 60% were vitamin D insufficient (Serum concentrations between 20–29 ng/ml or 50–74 nmol/l); and 30% of our study population were Vitamin D sufficient with Serum concentrations above 30 ng/ml (75 nmol/l) (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('UBERON_0001977', 'blood serum', 152, 'serum'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('UBERON_0001977', 'blood serum', 274, 'serum')]
S92-PMC4405493	PMC4405493	4/2015	S92-PMC4405493	['the mean Serum 25-Oh Vitamin D concentration for our study population was 27.6 ng/ml (range 13–71.6 ng/ml).10.1371/journal.pone.0123763.t001\n\ncaption (table-wrap): table 1\nfrequency of clinical outcomes compared to national and global epidemiology.Pregnancy outcome n (% of 235 total)comorbiditiespredicted population us (%)frequencies global (%)madigan 2014 (%) none 176 (75%)-------- Preeclampsia 19 (8%)5 Preterm Deliveries3–10% [22,24–26]2–17% [20,23]3% spontaneous Preterm Delivery 10 (4%)2 iugr, 1 Gdm11.3% [27]9.6% [28]9% iugr 9 (4%)--8.6% [29]3–7% [30]0.6% gdm 5 (2%)--4.6–9.2% [33]4.1–27.5% [36]4% spontaneous Abortion 16 (7%)--8–20% [37,38]6%\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.10.1371/journal.pone.0123763.t002\n\ncaption (table-wrap): table 2\ndemographics of the study population by Vitamin D classification.totalvitamin D sufficient (>30 ng/ml)Vitamin D insufficient (21–29 ng/ml)Vitamin D deficient (<20 ng/ml)p value**n = 235 (%)n = 70 (30%)n = 141 (60%)n = 24 (10%) age (years) *24.3 ± 4.424.5 ± 4.224.6 ± 4.522.5 ± 3.70.08 Gestational age at analysis (days) *62.2 ± 29.761.8 ± 13.762.2 ± 36.963.0 ± 11.20.99 n (% of 235)n (% of 70)n (% of 141)n (% of 24)p value ** race 0.03 caucasian 183 (77.9)57 (81.4)114 (80.9)12 (50) african american 16 (6.8)3 (4.3)10 (7.1)3 (12.5) asian 6 (2.6)1 (1.4)3 (2.1)2 (8.3) other 30 (12.8)9 (12.9)14 (9.9)7 (29.2) body mass index 0.36 <25 111 (47.2)39 (55.7)62 (44)10 (41.7) 25–30 82 (34.9)21 (30.0)50 (35.5)11 (45.8) >30 42 (17.9)10 (14.3)29 (20.5)3 (12.5) season 0.22 winter 89 (37.9)22 (31.4)61 (43.3)6 (25.0) spring 45 (19.1)16 (22.9)25 (17.7)4 (16.6) summer 53 (22.6)20 (28.6)26 (18.4)7 (29.2) fall 48 (20.4)12 (17.1)29 (20.6)7 (29.2) mode of delivery 0.41 Vaginal 155 (66.0)47 (67.1)95 (67.4)13 (54.2) cesarean section 63 (26.8)18 (25.7)36 (25.5)9 (37.5) iufd or sab 17 (7.2)5 (7.1)10 (7.1)2 (8.3) duty status 0.12 active duty 83 (35.3)22 (31.4)48 (34.0)13 (54.2) dependent 152 (64.6)48 (68.6)93 (66.0)11 (45.8) tobacco use 0.67 yes 15 (6.4)3 (4.3)10 (7.1)2 (8.3) no 220 (93.6)67 (95.7)131 (92.9)22 (91.7)\n*expressed in mean ± standard deviation\n**, p value calculated by analysis of variance for continuous variables and chi-square analysis for categorical variables\niufd, Intrauterine fetal demise; sab, spontaneous Abortion.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 15, '25-OH'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 248, 'Pregnancy'), ('GO_0007128', 'meiotic prophase I', 386, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 408, 'preterm'), ('GO_0007567', 'parturition', 416, 'deliveries3'), ('GO_0007565', 'female pregnancy', 470, 'preterm'), ('GO_0007567', 'parturition', 478, 'delivery'), ('PR_000007939', 'glial fibrillary acidic protein', 504, 'GDM11'), ('GO_0007569', 'cell aging', 619, 'abortion'), ('UBERON_0022293', 'reproductive gland secretion', 659, 'intrauterine'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('CHEBI_27300', 'vitamin D', 832, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 870, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 870, 'D'), ('CHEBI_28384', 'vitamin K', 894, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 930, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 930, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1077, 'Gestational'), ('UBERON_0000970', 'eye', 1748, 'Vaginal'), ('UBERON_0022293', 'reproductive gland secretion', 2266, 'intrauterine'), ('GO_0007569', 'cell aging', 2310, 'abortion')]
S5-PMC4930210	PMC4930210	7/2016	S5-PMC4930210	['25(Oh)D2, 25(Oh)D3, and 3-Epi-25(Oh)D3) were identified in all of the 537 Plasma samples;3-Epi-25(Oh)D3Contributed 5% of the total Vitamin D. the median (iqr) total 25(Oh)D (D2+d3) was 92.7 (30.4) nmol/l and 20% of women had 25(Oh)D concentration < 75 nmol/l.']	N/A	N/A	[('CHEBI_77765', '2,4,6-trihydroxybenzophenone(1-)', 0, '25(OH)D2'), ('CHEBI_62946', 'ammonium sulfate', 10, '25(OH)D3'), ('CHEBI_76959', '19-HEPE', 24, '3-epi-'), ('CHEBI_62946', 'ammonium sulfate', 30, '25(OH)D3'), ('UBERON_0001969', 'blood plasma', 74, 'plasma'), ('CHEBI_86390', '3-pyridylacetic acid', 89, '3-epi-25(OH)D3contributed'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 165, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 171, 'D'), ('CHEBI_37987', 'Cy3 dye', 174, 'D2'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D')]
S148-PMC4934634	PMC4934634	11/2015	S148-PMC4934634	['when the culture media was supplemented with Vitamin D in hypoxic conditions (used to stimulate the production and secretion of pro-inflammatory cytokines), Placental Tissue from preeclamptic Pregnancies Secreted significantly lower concentrations of hypoxia-induced Antiangiogenic factor, Sflt-1, and had diminished il-6 production compared to Preeclamptic Placentas cultured without vitamin D supplementation [57].']	N/A	N/A	"[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001987', 'placenta', 157, 'placental'), ('UBERON_0000479', 'tissue', 167, 'tissue'), ('GO_0007565', 'female pregnancy', 192, 'pregnancies'), ('GO_0046903', 'secretion', 204, 'secreted'), ('CHEBI_76219', 'fluorogen', 267, 'antiangiogenic'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 290, 'sFlt-1'), ('PR_000017511', ""5'-3' exoribonuclease 1"", 320, '6'), ('GO_0007565', 'female pregnancy', 345, 'preeclamptic'), ('UBERON_0001987', 'placenta', 358, 'placentas'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 393, 'D')]"
S30-PMC4998950	PMC4998950	4/2016	S30-PMC4998950	['caption (table-wrap): table 2\nodds ratios (ors) and 95% confidence intervals (cis) for autism spectrum disorder (asd), with and without comorbid intellectual disability, in relation to lifetime maternal history of diagnosed Vitamin D deficiencyvitamin D deficiencycasesor (95% ci)aor (95% ci)bor (95% ci)call asd\u2003no98591.00 (ref)1.00 (ref)1.00 (ref)\u2003yes232.20 (1.35–3.58)1.70 (1.03–2.79)1.78 (1.08–2.92)asd with intellectual disability\u2003no24631.00 (ref)1.00 (ref)1.00 (ref)\u2003yes135.08 (2.53–10.20)3.55 (1.76–7.18)2.51 (1.22–5.16)asd without intellectual disability\u2003no73961.00 (ref)1.00 (ref)1.00 (ref)\u2003yes101.23 (0.67–2.28)0.99 (0.52–1.87)1.28 (0.68–2.42)\nadjusted for year of Birth and gender.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 252, 'D'), ('GO_0007567', 'parturition', 675, 'birth')]
S63-PMC5146866	PMC5146866	12/2016	S63-PMC5146866	['caption (table-wrap): table 1\n\nmaternal demographics and clinical characteristics with respect to cb Vitamin D statusparametricvitamin D status p valuedeficiency n \u2009=\u200995insufficiency n \u2009=\u200979sufficiency n \u2009=\u200991age (years)30.6+/−5.7(29.4–31.8)29.9+/−5.1(28.8–31.1)32.6+/−5.3(31.5–33.8)<0.01medicaid/uninsured16.0%(9.9–24.7)8.8%(4.3–16.9)6.7%(3.1–13.6)0.09weight at Birth (pounds)175+/−41(167–183)172+/−34(165–180)174+/−39(166–182)0.89multiple Gestation1.1%(0.002–0.06)1.3%(0.002–0.07)3.3%(0.11–0.09)0.47nulliparity (%)27.7%(19.6–37.4)38.8%(28.8–49.7)36.3%(27.1–46.5)0.26first gravidity (%)21.3%(9.1–23.5)26.3%(14.7–32.8)31.9%(6.9–20.4)0.56gravidity (number)3.4+/−2.4(2.9–3.9)2.8+/−1.9(2.3–3.2)2.4+/−1.3(2.1–2.6)<0.01gestational age38.9+/−1.3(38.6–39.1)39.2+/−1.2(38.9–39.5)39.0+/−1.3(38.7–39.3)0.15winter season Deliveries14.9%(9.1–23.5)22.5%(14.7–32.8)12.1%(6.9–20.4)0.17cesarean section32.9%(24.3–42.9)35.0%(25.5–45.9)41.8%(32.2–52.1)0.44vitamins supplementation66.0%(60.3–78.5)77.5%(67.2–85.3)67.0%(56.9–75.8)0.20iron supplementation8.5%(4.4–15.9)3.8%(1.3–10.5)2.2%(0.6–7.7)0.15thyroid medications9.6%(5.1–17.2)8.8%(4.3–16.9)8.8%(4.5–16.4)0.98substance abuse (smoking/alcohol/Drugs)3.2%(1.1–8.9)5.0%(2.0–12.2)6.6%(3.1–13.6)0.56morbidities during Pregnancy21.3%(14.2–30.6)26.3%(17.9–36.8)23.1%(15.6–32.7)0.74diabetes10.6%(5.9–18.5)12.5%(6.9–21.5)7.7%(3.8–15.1)0.57\ndata presented as mean or proportion (%) with 95% confidence interval\n\ncaption (fig): fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('GO_0007567', 'parturition', 363, 'birth'), ('GO_0007565', 'female pregnancy', 441, 'gestation1'), ('GO_0060179', 'male mating behavior', 810, 'deliveries14'), ('CHEBI_23888', 'drug', 1177, 'drugs'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy21')]
S45-PMC5167470	PMC5167470	12/2016	S45-PMC5167470	['a strict monitoring and biochemical follow-up of Pregnant women taking high doses of Vitamins A and D significantly minimizes the risk for developing adverse events.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 85, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 94, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 100, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 100, 'D')]
S52-PMC5332602	PMC5332602	3/2017	S52-PMC5332602	['concentrations of protein, Albumin, and Glucose in the Serum of protein-deficient and -sufficient Hifm/Hrv-infected Pigs ( n = 10/group) were determined at marshfield labs (marshfield, wi), and Selenium, Vitamin A and E concentrations in the Serum of protein-deficient and -sufficient hifm/hrv-infected Pigs ( n = 8/group) were measured at the diagnostic center for population and Animal health (michigan state university, east lansing, mi) by high-performance liquid chromatography.']	N/A	N/A	[('PR_000005908', 'alpha-crystallin B chain', 27, 'albumin'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 98, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 103, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'pigs'), ('CHEBI_27568', 'selenium atom', 194, 'selenium'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 218, 'E'), ('UBERON_0001977', 'blood serum', 242, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 303, 'pigs'), ('NCBITaxon_33208', 'Metazoa', 381, 'Animal')]
S279-PMC5332602	PMC5332602	3/2017	S279-PMC5332602	['the frequencies of cell populations in flow cytometry and Serum Glucose, protein, albumin, Lps, Vitamin A ands E, and Selenium levels were compared among groups with the kruskal-wallis rank sum and mann-whitney (nonparametric) tests.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('CHEBI_16412', 'lipopolysaccharide', 91, 'LPS'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 111, 'E'), ('CHEBI_27568', 'selenium atom', 118, 'selenium')]
S197-PMC5396145	PMC5396145	10/2016	S197-PMC5396145	['for absolute mean Intakes, women in the ‘white bread and coffee’ cluster had the lowest intake of energy and all Nutrients, while those in the ‘meat and potatoes’ cluster had the highest absolute mean intakes of energy and most Macronutrients except total N‐3 highly unsaturated Fatty Acids and fibre and the highest absolute mean intakes of most Micronutrients except Magnesium, Carotene, Folate, Vitamins C and D (table3).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 18, 'intakes'), ('CHEBI_33284', 'nutrient', 113, 'nutrients'), ('CHEBI_33839', 'macromolecule', 228, 'macronutrients'), ('31', 'ACACA (human)', 256, 'n'), ('CHEBI_35366', 'fatty acid', 279, 'fatty acids'), ('CHEBI_33839', 'macromolecule', 347, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 369, 'magnesium'), ('CHEBI_23042', 'carotene', 380, 'carotene'), ('CHEBI_30863', '5-azaorotic acid', 390, 'folate'), ('CHEBI_27300', 'vitamin D', 398, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 413, 'D')]
S198-PMC5396145	PMC5396145	10/2016	S198-PMC5396145	['women in the ‘fruit and vegetables’ cluster had the highest absolute mean Intakes of Docosahexaenoic Acid (Dha), Eicosapentaenoic Acid (Epa) and total n‐3 highly unsaturated Fatty Acids, fibre, Magnesium, Carotene, Folate, Vitamin C and D (table3).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 74, 'intakes'), ('CHEBI_36003', 'decenoic acid', 85, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 107, 'DHA'), ('CHEBI_36003', 'decenoic acid', 113, 'eicosapentaenoic acid'), ('CHEBI_34733', 'EPN', 136, 'EPA'), ('CHEBI_35366', 'fatty acid', 174, 'fatty acids'), ('CHEBI_22313', 'alkaline earth metal atom', 194, 'magnesium'), ('CHEBI_23042', 'carotene', 205, 'carotene'), ('CHEBI_30863', '5-azaorotic acid', 215, 'folate'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 237, 'D')]
S93-PMC5513133	PMC5513133	7/2017	S93-PMC5513133	['search terms: (Preeclampsia or pre-eclampsia) and (Vitamin D or hypovitaminosis D or 1,25 Dihydroxyvitamin D or (Vitamin D and (supplementation or supplement)) or Dihydroxyvitamin D or 25 Hydroxyvitamin D).']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 15, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 80, 'D'), ('CHEBI_67469', '15-hydroxyajubractin C', 85, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27481', 'rhodexin A', 163, 'dihydroxyvitamin D'), ('CHEBI_37972', 'phosphorus-32 atom', 185, '25'), ('CHEBI_67825', '17beta,21beta-epoxyhopan-3-one', 188, 'hydroxyvitamin D')]
S65-PMC5546866	PMC5546866	8/2017	S65-PMC5546866	['in addition, in women randomized to Cholecalciferol, we assessed the relationship between the Snps and the change in Vitamin D using the residuals of 25(Oh)D at 34 weeks of Gestation Regressed on 25(Oh)D at 14 weeks of Gestation as the outcome.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 36, 'cholecalciferol'), ('SO_0000694', 'SNP', 94, 'SNPs'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 150, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 156, 'D'), ('GO_0007565', 'female pregnancy', 173, 'gestation'), ('GO_0060033', 'anatomical structure regression', 183, 'regressed'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 202, 'D'), ('GO_0007565', 'female pregnancy', 219, 'gestation')]
S87-PMC5732505	PMC5732505	12/2017	S87-PMC5732505	['p -values refer to differences between the groupsmaternal characteristics n non-gdm n gdm p valueage at Delivery (y)64231.4\xa0±\xa04.38132.7\xa0±\xa04.50.018level of educationa6325.0\xa0±\xa01.3794.7\xa0±\xa01.40.051parity6401.5\xa0±\xa00.7811.5\xa0±\xa00.70.275prepregnancy smoking, number of cigarettes daily6251.2\xa0±\xa03.7762.0\xa0±\xa04.60.064alcohol consumption before Pregnancy, portion/wk.6251.9\xa0±\xa02.0782.3\xa0±\xa03.50.755prepregnancy height (cm)642166.3\xa0±\xa06.081165.9\xa0±\xa05.40.398prepregnancy weight (kg)63163.5\xa0±\xa010.28172.1\xa0±\xa013.5<0.001prepregnancy bmi (kg/m2)63923.0\xa0±\xa03.58126.2\xa0±\xa04.8<0.001duration of Gestation at ogtt (wk)32326.3\xa0±\xa04.38025.9\xa0±\xa05.90.774duration of Gestation at Pregnancy Blood sampling (wk)64211.3\xa0±\xa01.98111.2\xa0±\xa02.20.089duration of Gestation at Delivery (wk)64240.2\xa0±\xa01.18140.1\xa0±\xa01.10.410pregnancy 25(Oh)D (nmol/l)64281.9\xa0±\xa019.58180.0\xa0±\xa021.20.417ucb 25(Oh)D (nmol/l)64280.1\xa0±\xa020.08178.4\xa0±\xa018.80.448supplemental Vitamin D intake during Pregnancy ( μ g/d)62115.5\xa0±\xa016.67613.5\xa0±\xa010.80.162cumulative Gestational weight gain atb(kg)0.093\u2003first measurement5801.7\xa0±\xa00.5741.6\xa0±\xa00.5\u200312th Gestational week5803.8\xa0±\xa01.0743.6\xa0±\xa01.1\u200320th Gestational week5806.3\xa0±\xa00.8746.2\xa0±\xa00.8\u200330th Gestational week5809.7\xa0±\xa00.5749.7\xa0±\xa00.4\u2003last measurement58013.8\xa0±\xa00.47413.7\xa0±\xa00.3\ngdm Gestational diabetes mellitus, 25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical cord Blood\nvalues are means ± sd\nascale from 1\u2009=\u2009lower secondary education to 6\u2009=\u2009first or second stage of tertiary education\nbvalues are adjusted for duration of Gestation\nindependent sample t-tests, mann-whitney u-tests, repeated measures anova or the pearson chi-square test, when appropriate, were applied to compare maternal characteristics between gdm and non-gdm mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 104, 'delivery'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 560, 'gestation'), ('GO_0007565', 'female pregnancy', 624, 'gestation'), ('GO_0007565', 'female pregnancy', 637, 'pregnancy'), ('UBERON_0000178', 'blood', 647, 'blood'), ('GO_0007565', 'female pregnancy', 708, 'gestation'), ('GO_0007567', 'parturition', 721, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 774, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 826, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 832, 'D'), ('CHEBI_27300', 'vitamin D', 887, 'vitamin D'), ('GO_0007565', 'female pregnancy', 911, 'pregnancy'), ('GO_0007565', 'female pregnancy', 972, 'gestational'), ('GO_0007565', 'female pregnancy', 1055, 'gestational'), ('GO_0007565', 'female pregnancy', 1100, 'gestational'), ('GO_0007565', 'female pregnancy', 1145, 'gestational'), ('GO_0007565', 'female pregnancy', 1231, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1262, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1270, '25-hydroxy vitamin D'), ('UBERON_0007118', 'umbilicus', 1296, 'umbilical'), ('UBERON_0000178', 'blood', 1311, 'blood'), ('GO_0007565', 'female pregnancy', 1469, 'gestation')]
S10-PMC5758521	PMC5758521	1/2018	S10-PMC5758521	['the common circulating forms of Vitamins A and E include Α- and γ-tocopherols for Vitamin E3, Retinol for Vitamin A, and Β-Carotene for Provitamin A4.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 32, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'E'), ('CHEBI_16199', 'urea', 57, 'α-'), ('CHEBI_33237', 'vitamin D4', 82, 'vitamin E3'), ('PR_000017264', 'synaptic vesicle membrane protein VAT-1', 82, 'vitamin E3'), ('CHEBI_26536', 'retinoic acid', 94, 'retinol'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 121, 'β-carotene'), ('PR_000012529', 'PDZK1-interacting protein 1', 136, 'provitamin A4')]
S33-PMC5758521	PMC5758521	1/2018	S33-PMC5758521	['for assessing Vitamin A and E nutritional status in fetuses/neonates, Retinol, Β-Carotene, Α-Tocopherol and Γ-Tocopherol in edta cord plasma specimens were measured by high-performance liquid chromatography (hplc)18.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 28, 'E'), ('CHEBI_26536', 'retinoic acid', 70, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 79, 'β-carotene'), ('CHEBI_27725', 'butin', 91, 'α-tocopherol'), ('CHEBI_27725', 'butin', 108, 'γ-tocopherol')]
S89-PMC5812027	PMC5812027	2/2018	S89-PMC5812027	['1\n\nflow chart of the study inclusion\n\ncaption (table-wrap): table 1\n\ncharacteristics of the Pregnant women and their infants at Birthmeansdbirth weight (grams)a3542537.7birth length (cm)a502.3gestational age at Delivery (days)28012.4gestational age t1 (days)7613.8gestational age t3 (days)23412.9maternal s-25Ohd t1 (nmol/l)6424.4maternal s-25Ohd t3 (nmol/l)7534.4n (%)male gender of infanta976 (49.8)small for Gestational age (weight or length)93 (4.5)low Birth weight (<\u20092500\xa0g)58 (2.8)Preterm Delivery (<\u200937\xa0weeks)78 (3.8)spontaneous Preterm Delivery (<\u200937\xa0weeks)55 (2.7)Pregnancy loss97 (4.7)Intrauterine fetal death (≥\u200922\xa0weeks)9 (0.5)\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\nalive Born infants only\n\ncaption (table-wrap): table 2\n\nthe Pregnant women’s Vitamin D status in the first (t1) and third (t3) Trimester of Pregnancy, and their characteristics (mean or percent) grouped by 25Ohd concentration in (t1)t1 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n198291788565125%10.114.840.128.76.4bmi t1 (kg/m2)25.124.924.423.924.4age t1 (years)29.430.931.632.032.4born in sweden (%)14.154.683.387.893.5tobacco use t1 (%)6.84.64.04.61.6nulliparous t1 (%)34.842.042.643.142.7vitamin D supplement use t1 (%)10.628.245.256.662.9university level education (%)32.354.961.367.366.1small for Gestational age (%)5.74.25.34.14.0preterm Delivery (%)4.15.23.83.91.6low Birth weight (%)3.04.53.12.11.6pregnancy loss (%)6.35.64.55.10t3 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n163330473409443%9.018.226.022.524.4small for Gestational age (%)7.55.54.74.62.3preterm Delivery (%)4.31.23.62.21.6low Birth weight (%)4.30.32.71.21.4\nt1 first trimester, t3 third trimester, 25Ohd 25-hydroxyvitamin d\n\nBirth size and Preterm Delivery\nin total, 93 (4.5%) infants were Born sga.']	N/A	N/A	"[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('GO_0002211', 'behavioral defense response to insect', 128, 'birthMeanSDBirth'), ('GO_0007567', 'parturition', 211, 'delivery'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 307, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 341, '25OHD'), ('GO_0007565', 'female pregnancy', 411, 'gestational'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007128', 'meiotic prophase I', 488, 'Preterm'), ('GO_0007567', 'parturition', 496, 'delivery'), ('GO_0007565', 'female pregnancy', 537, 'preterm'), ('GO_0007567', 'parturition', 545, 'delivery'), ('GO_0007565', 'female pregnancy', 574, 'Pregnancy'), ('UBERON_0035108', 'temporalis fascia', 596, 'Intrauterine'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 681, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 687, '25-hydroxyvitamin D'), ('GO_0007567', 'parturition', 713, 'born'), ('GO_0007565', 'female pregnancy', 767, 'pregnant'), ('CHEBI_27300', 'vitamin D', 784, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 834, 'trimester'), ('GO_0007565', 'female pregnancy', 847, 'pregnancy'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 913, '25OHD'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 943, '25OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1208, 'D'), ('GO_0007565', 'female pregnancy', 1311, 'gestational'), ('GO_0007567', 'parturition', 1353, 'delivery'), ('GO_0007567', 'parturition', 1384, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1449, '25OHD'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('GO_0007567', 'parturition', 1581, 'delivery'), ('GO_0007567', 'parturition', 1612, 'birth'), ('CHEBI_72652', ""7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation"", 1684, '25OHD'), ('GO_0007567', 'parturition', 1711, 'Birth'), ('GO_0007565', 'female pregnancy', 1726, 'preterm'), ('GO_0007567', 'parturition', 1734, 'delivery'), ('GO_0007567', 'parturition', 1776, 'born')]"
S21-PMC5952272	PMC5952272	5/2018	S21-PMC5952272	['Micronutrient supplementation includes Folic Acid tablets 3\u2009months before Pregnancy and 3\u2009months Postnatal, Vitamin A and D drops for infant starting from Birth until 12\u2009months, and Iron and Folic Acid tablets for Pregnant women 3\u2009months after Conception until 3\u2009months Postnatal.']	N/A	N/A	[('CHEBI_6956', 'Mitragynine', 0, 'Micronutrient'), ('CHEBI_30751', 'formic acid', 39, 'folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'postnatal'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'D'), ('GO_0007567', 'parturition', 155, 'birth'), ('CHEBI_24870', 'ion', 182, 'iron'), ('CHEBI_30751', 'formic acid', 191, 'folic acid'), ('GO_0007565', 'female pregnancy', 214, 'pregnant'), ('GO_0007620', 'copulation', 244, 'conception'), ('GO_0007567', 'parturition', 270, 'postnatal')]
